Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial

著录项

• 来源
  《Europace: European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology》 |2019年第7期|共16页
• 作者

  Alak Aiman; Hohnloser Stefan H.; Fraessdorf Mandy; Reilly Paul; Ezekowitz Michael; Healey Jeff S.; Brueckmann Martina; Yusuf Salim; Connolly Stuart J.;

  展开▼
• 作者单位

  McMaster Univ Dept Med PHRI 30 Birge St Hamilton ON L8L 0A6 Canada;

  Goethe Univ Frankfurt Dept Cardiol Frankfurt Germany;

  Boehringer Ingelheim GmbH &

  Co KG Ingelheim Germany;

  Boehringer Ingelheim Pharmaceut Inc 90 E Ridge POB 368 Ridgefield CT 06877 USA;

  Thomas Jefferson Univ Sidney Kimmel Med Coll Philadelphia PA 19107 USA;

  McMaster Univ Dept Med PHRI 30 Birge St Hamilton ON L8L 0A6 Canada;

  Heidelberg Univ Fac Med Mannheim Germany;

  McMaster Univ Dept Med PHRI 30 Birge St Hamilton ON L8L 0A6 Canada;

  McMaster Univ Dept Med PHRI 30 Birge St Hamilton ON L8L 0A6 Canada;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 内科学;
• 关键词

  Atrial fibrillation; Hospitalization; Anticoagulation; Dabigatran; Mortality;

  机译：心房颤动;住院;抗凝;Dabigatran;死亡率;